RxDoctor Payments DataLook up a doctor →

Janet Pan, MD

Hematology-Oncology · Fountain Valley, CANPI 1801056676

Payments from drug & device makers

$155,847in general payments, 2019–2025

Across 2,332 payments — averaging $66.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bristol Myers Squibb$97K
  • E.r. Squibb & Sons, L.L.C.$16K
  • AstraZeneca$4K
  • Johnson & Johnson$3K
  • Novartis$2K
  • Merck$2K
  • plus $30K from 54 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Bristol Myers Squibb107$96,607
E.r. Squibb & Sons, L.L.C.156$16,162
AstraZeneca(2 entities)177$3,963
Johnson & Johnson134$2,755
Novartis127$2,419
Merck98$2,108
Incyte Corporation95$2,097
Eisai Inc.76$1,675
Pfizer100$1,615
Amgen74$1,584
Bayer86$1,364
Seagen Inc.58$1,220
AbbVie65$1,193
Gilead(2 entities)60$1,191
GSK55$1,179
Astellas Pharma US Inc54$1,153
Exelixis Inc.41$1,103
Takeda Pharmaceuticals U.S.A., Inc.45$1,078
Pharmacyclics LLC, An Abbvie Company63$1,003
Lilly USA, LLC42$892
Genentech USA, Inc.39$868
Puma Biotechnology, Inc.38$819
Array Biopharma Inc45$788
Regeneron Healthcare Solutions, Inc.24$684
Daiichi Sankyo Inc.30$624
Coherus Oncology, Inc.27$547
Sanofi25$543
Karyopharm Therapeutics Inc.21$539
Beigene USA, Inc.14$528
Boehringer Ingelheim23$438
Blueprint Medicines Corporation13$383
EMD Serono, Inc.20$379
AVEO Pharmaceuticals, Inc.13$351
Taiho Oncology, Inc.16$295
Stemline Therapeutics Inc.11$281
Jazz Pharmaceuticals Inc.11$273
Foundation Medicine, Inc.8$273
Sumitomo Pharma America, Inc.18$273
Sobi, Inc12$259
Myovant Sciences Inc.16$253
Rigel Pharmaceuticals, Inc.14$252
Morphosys, US Inc.12$230
ADC Therapeutics America, Inc.6$228
Ipsen Biopharmaceuticals, Inc11$196
Pharmaessentia USA Corporation6$186
Servier Pharmaceuticals LLC6$128
AMAG Pharmaceuticals, Inc.6$121
Tersera Therapeutics LLC4$112
Beone Medicines USA, Inc.4$111
Agios Pharmaceuticals, Inc.5$110
Genmab U.S., Inc.4$107
Recordati_rare_diseases_inc.5$106
Sanofi-aventis U.S. LLC1$100
Immunogen, Inc.4$95
Pharmacosmos Therapeutics Inc.5$91
Clovis Oncology, Inc.5$90
Deciphera Pharmaceuticals Inc.4$89
Adaptive Biotechnologies Corporation4$88
Dendreon Pharmaceuticals LLC4$84
Geron Corporation3$81

How this compares

$155,847 in reported general payments places this provider in the 75th percentile of 53 hematology-oncology providers in California.

See all hematology-oncology providers in California

Medicare billing

Part B allowed, 2024
$671,349
Medicare patients
131
Services billed
27,707

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology-oncology in Fountain Valley

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →